328 related articles for article (PubMed ID: 12478252)
41. Scrutiny of gene therapy broadens, intensifies.
Fox JL
Nat Biotechnol; 2000 Apr; 18(4):377. PubMed ID: 10748511
[No Abstract] [Full Text] [Related]
42. More flexibility on reporting to federal agencies about injuries to research subjects.
Maloney DM
Hum Res Rep; 2002 Jan; 17(1):1-2. PubMed ID: 16270435
[No Abstract] [Full Text] [Related]
43. NIH panel to limit secrecy on gene therapy.
Wadman M
Nature; 1999 Nov; 402(6757):6. PubMed ID: 10573406
[No Abstract] [Full Text] [Related]
44. Gene therapy: X-SCID transgene leukaemogenicity.
Thrasher AJ; Gaspar HB; Baum C; Modlich U; Schambach A; Candotti F; Otsu M; Sorrentino B; Scobie L; Cameron E; Blyth K; Neil J; Abina SH; Cavazzana-Calvo M; Fischer A
Nature; 2006 Sep; 443(7109):E5-6; discussion E6-7. PubMed ID: 16988659
[TBL] [Abstract][Full Text] [Related]
45. Genes can come true.
Phillips H
New Sci; 2002 Nov; 176(2371):30-3. PubMed ID: 12731520
[No Abstract] [Full Text] [Related]
46. Biotechnology on the RAC--FDA/NIH regulation of human gene therapy.
Rainsbury JM
Food Drug Law J; 2000; 55(4):575-600. PubMed ID: 12025851
[No Abstract] [Full Text] [Related]
47. Safeguards for gene therapy trials.
FDA Consum; 2003; 37(3):5. PubMed ID: 12793378
[No Abstract] [Full Text] [Related]
48. Investigation of gene therapy begins.
Fox JL
Nat Biotechnol; 2000 Feb; 18(2):143-4. PubMed ID: 10657112
[No Abstract] [Full Text] [Related]
49. Gene therapy investigations proliferate.
Hollon T
Nat Med; 2000 Mar; 6(3):235. PubMed ID: 10700200
[No Abstract] [Full Text] [Related]
50. A tumultuous year for gene therapy.
Verma IM
Mol Ther; 2000 Nov; 2(5):415-6. PubMed ID: 11082313
[No Abstract] [Full Text] [Related]
51. Clinical trials end at gene-therapy institute..
Smaglik P
Nature; 2000 Jun; 405(6786):497. PubMed ID: 10850679
[No Abstract] [Full Text] [Related]
52. Gene therapy. RAC hears a plea for resuming trials, despite cancer risk.
Kaiser J
Science; 2003 Feb; 299(5609):991. PubMed ID: 12586909
[No Abstract] [Full Text] [Related]
53. US plans to protect clinical research participants.
Fox JL
Nat Biotechnol; 2000 Jul; 18(7):709. PubMed ID: 10888829
[No Abstract] [Full Text] [Related]
54. FDA given new powers over data reporting to national clinical trials registry.
Roehr B
BMJ; 2012 Oct; 345():e6629. PubMed ID: 23033375
[No Abstract] [Full Text] [Related]
55. Gene therapists promise renewed vigor in monitoring as field progresses.
SoRelle R
Circulation; 2001 Jan; 103(1):E9001-2. PubMed ID: 11136706
[No Abstract] [Full Text] [Related]
56. Safety testing programs for gene therapy viral vectors.
Ostrove JM
Cancer Gene Ther; 1994 Jun; 1(2):125-31. PubMed ID: 7621244
[No Abstract] [Full Text] [Related]
57. Gene therapy. Panel urges limits on X-SCID trials.
Kaiser J
Science; 2005 Mar; 307(5715):1544-5. PubMed ID: 15761128
[No Abstract] [Full Text] [Related]
58. Gene therapy--a loss of innocence.
Nat Med; 2000 Jan; 6(1):1. PubMed ID: 10613791
[No Abstract] [Full Text] [Related]
59. Human gene therapy. Harsh lessons, high hopes.
Thompson L
FDA Consum; 2000; 34(5):19-24. PubMed ID: 11590787
[No Abstract] [Full Text] [Related]
60. Fifteen-year follow up for gene therapy patients.
Birmingham K
Nat Med; 2001 Dec; 7(12):1263. PubMed ID: 11726945
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
